Omnicell (NASDAQ:OMCL) Releases Q1 2025 Earnings Guidance

Omnicell (NASDAQ:OMCL) issued an update on its first quarter 2025 earnings guidance on Friday morning. The company provided EPS guidance of 0.150-0.250 for the period, compared to the consensus EPS estimate of 0.210. The company issued revenue guidance of $255.0 million-$265.0 million, compared to the consensus revenue estimate of $260.2 million. Omnicell also updated its FY 2025 guidance to 1.650-1.850 EPS.

Wall Street Analyst Weigh In

A number of brokerages have commented on OMCL. JPMorgan Chase & Co. reduced their target price on shares of Omnicell from $44.00 to $36.00 and set a “neutral” rating for the company in a report on Thursday, March 20th. StockNews.com lowered Omnicell from a “buy” rating to a “hold” rating in a research note on Monday, March 24th. Benchmark reiterated a “buy” rating and set a $62.00 target price on shares of Omnicell in a research report on Tuesday, February 4th. Bank of America reduced their price target on Omnicell from $54.00 to $46.00 and set a “neutral” rating for the company in a research report on Monday, January 6th. Finally, Wells Fargo & Company cut their price objective on Omnicell from $49.00 to $40.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. Five investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Omnicell presently has an average rating of “Hold” and a consensus price target of $51.00.

Omnicell Stock Performance

OMCL opened at $35.01 on Friday. The company has a fifty day moving average of $39.01 and a 200 day moving average of $42.58. Omnicell has a fifty-two week low of $25.12 and a fifty-two week high of $55.75. The stock has a market capitalization of $1.64 billion, a price-to-earnings ratio of 129.67, a PEG ratio of 7.53 and a beta of 0.85. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.22 and a current ratio of 1.37.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings results on Thursday, February 6th. The company reported $0.45 EPS for the quarter, missing analysts’ consensus estimates of $0.57 by ($0.12). Omnicell had a net margin of 1.13% and a return on equity of 3.82%. As a group, sell-side analysts forecast that Omnicell will post 1.09 earnings per share for the current fiscal year.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.